Sorrento Therapeutics Inc (SRNE): The anti-PD-L1 antibody has many combina...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	57
Posts	5700
Boards Moderated	0
Alias Born	12/13/2004

dia76ca

Re: dia76ca post# 8917

Monday, 03/08/2021 12:07:34 PM

Monday, March 08, 2021 12:07:34 PM

The anti-PD-L1 antibody has many combination applications in cervical, osteosarcoma, urothelial, small cell lung, and esophageal cancer indications! Sorrento will receive milestone and royalty payments from China and has full rights in ROW. Apparently it moved straight from a phase 1b to a phase III trial in SCLC. Very impressive!

"The refusal of the real is the number one dogma of our time" Rene Girard

Keep Last Read

Replies (2) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent SRNE News

Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM